In the last 20 years, following the identification of the BRCA1 and BRCA2 genes (hereinafter referred to as the BRCA genes), preventive pathways have been developed for the identification and clinical management of individuals at high risk of developing breast and ovarian cancer due to the presence of a pathogenic variant in either of these genes. These pathways are aimed at educating high-risk subjects on programs targeted toward early diagnosis and cancer risk reduction. The approval of a novel class of drugs, the PARP enzyme inhibitors, for the treatment of ovarian cancer patients carrying high-risk BRCA pathogenic variants has changed this scenario. BRCA testing, in addition to providing information on the risk of disease, has become also a predictive marker of drug response in ovarian carcinoma patients. These recommendations prepared by Associazione Italiana di Oncologia Medica (AIOM), Società Italiana Genetica Umana (SIGU), Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBIOC) and Società Italiana di Anatomia Patologica e Citologia Diagnostica – Italian Division of the International Academy of Pathology (SIAPEC-IAP) are focused on the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.

Pinto, C., Bella, M. A., Capoluongo, E. D., Carrera, P., Clemente, C., Colombo, N., Cortesi, L., De Rosa, G., Fenizia, F., Genuardi, M., Gori, S., Guarneri, V., Marchetti, A., Marchetti, P., Normanno, N., Pasini, B., Pignata, S., Radice, P., Ricevuto, E., Dello Russo, A., Tagliaferri, P., Tassone, P., Truini, M., Varesco, L., Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients, <<FUTURE ONCOLOGY>>, 2016; 12 (18): 2071-2075. [doi:10.2217/fon-2016-0189] [http://hdl.handle.net/10807/93649]

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients

Capoluongo, Ettore Domenico;Genuardi, Maurizio;Marchetti, Paolo;Dello Russo, Antonio;Varesco, Liliana
Ultimo
2016

Abstract

In the last 20 years, following the identification of the BRCA1 and BRCA2 genes (hereinafter referred to as the BRCA genes), preventive pathways have been developed for the identification and clinical management of individuals at high risk of developing breast and ovarian cancer due to the presence of a pathogenic variant in either of these genes. These pathways are aimed at educating high-risk subjects on programs targeted toward early diagnosis and cancer risk reduction. The approval of a novel class of drugs, the PARP enzyme inhibitors, for the treatment of ovarian cancer patients carrying high-risk BRCA pathogenic variants has changed this scenario. BRCA testing, in addition to providing information on the risk of disease, has become also a predictive marker of drug response in ovarian carcinoma patients. These recommendations prepared by Associazione Italiana di Oncologia Medica (AIOM), Società Italiana Genetica Umana (SIGU), Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBIOC) and Società Italiana di Anatomia Patologica e Citologia Diagnostica – Italian Division of the International Academy of Pathology (SIAPEC-IAP) are focused on the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.
Inglese
Pinto, C., Bella, M. A., Capoluongo, E. D., Carrera, P., Clemente, C., Colombo, N., Cortesi, L., De Rosa, G., Fenizia, F., Genuardi, M., Gori, S., Guarneri, V., Marchetti, A., Marchetti, P., Normanno, N., Pasini, B., Pignata, S., Radice, P., Ricevuto, E., Dello Russo, A., Tagliaferri, P., Tassone, P., Truini, M., Varesco, L., Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients, <<FUTURE ONCOLOGY>>, 2016; 12 (18): 2071-2075. [doi:10.2217/fon-2016-0189] [http://hdl.handle.net/10807/93649]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/93649
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 18
social impact